Penumbra (PEN) Revenue & Revenue Breakdown
Penumbra Revenue Highlights
Latest Revenue (Y)
$1.06B
Latest Revenue (Q)
$301.04M
Main Segment (Y)
Peripheral Vascular
Main Geography (Y)
UNITED STATES
Penumbra Revenue by Period
Penumbra Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $1.06B | 24.95% |
| 2022-12-31 | $847.13M | 13.32% |
| 2021-12-31 | $747.59M | 33.40% |
| 2020-12-31 | $560.41M | 2.38% |
| 2019-12-31 | $547.40M | 23.03% |
| 2018-12-31 | $444.94M | 33.31% |
| 2017-12-31 | $333.76M | 26.75% |
| 2016-12-31 | $263.32M | 41.50% |
| 2015-12-31 | $186.09M | 48.27% |
| 2014-12-31 | $125.51M | 41.26% |
| 2013-12-31 | $88.85M | 21.47% |
| 2012-12-31 | $73.14M | - |
Penumbra generated $1.06B in revenue during NA 2023, up 24.95% compared to the previous quarter, and up 237.90% compared to the same period a year ago.
Penumbra Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $301.04M | 0.55% |
| 2024-06-30 | $299.40M | 7.45% |
| 2024-03-31 | $278.65M | -2.12% |
| 2023-12-31 | $284.68M | 5.07% |
| 2023-09-30 | $270.95M | 3.61% |
| 2023-06-30 | $261.50M | 8.33% |
| 2023-03-31 | $241.40M | 9.12% |
| 2022-12-31 | $221.22M | 3.53% |
| 2022-09-30 | $213.68M | 2.56% |
| 2022-06-30 | $208.34M | 2.18% |
| 2022-03-31 | $203.90M | -0.06% |
| 2021-12-31 | $204.01M | 7.31% |
| 2021-09-30 | $190.12M | 3.18% |
| 2021-06-30 | $184.26M | 8.90% |
| 2021-03-31 | $169.20M | 1.38% |
| 2020-12-31 | $166.90M | 10.47% |
| 2020-09-30 | $151.08M | 43.73% |
| 2020-06-30 | $105.11M | -23.46% |
| 2020-03-31 | $137.33M | -5.46% |
| 2019-12-31 | $145.26M | 4.13% |
| 2019-09-30 | $139.50M | 3.95% |
| 2019-06-30 | $134.20M | 4.49% |
| 2019-03-31 | $128.44M | 6.33% |
| 2018-12-31 | $120.79M | 8.04% |
| 2018-09-30 | $111.81M | 1.98% |
| 2018-06-30 | $109.64M | 6.75% |
| 2018-03-31 | $102.70M | 6.92% |
| 2017-12-31 | $96.05M | 14.47% |
| 2017-09-30 | $83.91M | 4.12% |
| 2017-06-30 | $80.59M | 10.07% |
| 2017-03-31 | $73.21M | 0.15% |
| 2016-12-31 | $73.11M | 8.81% |
| 2016-09-30 | $67.19M | 3.20% |
| 2016-06-30 | $65.11M | 12.41% |
| 2016-03-31 | $57.92M | 6.44% |
| 2015-12-31 | $54.42M | 7.93% |
| 2015-09-30 | $50.42M | 19.16% |
| 2015-06-30 | $42.31M | 8.62% |
| 2015-03-31 | $38.95M | 10.02% |
| 2014-12-31 | $35.40M | 9.05% |
| 2014-09-30 | $32.46M | - |
Penumbra generated $301.04M in revenue during Q3 2024, up 0.55% compared to the previous quarter, and up 115.12% compared to the same period a year ago.
Penumbra Revenue Breakdown
Penumbra Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| Neuro | $347.74M | $338.71M | $292.63M | $331.69M | $294.33M |
| Peripheral Vascular | $499.39M | $408.88M | $267.78M | $215.72M | $150.60M |
Penumbra's latest annual revenue breakdown by segment (product or service), as of Dec 22: Peripheral Vascular (58.95%), and Neuro (41.05%).
Quarterly Revenue by Product
| Product/Service | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Peripheral Vascular | $99.54M | $152.68M | $142.85M | $123.36M | $123.54M | $122.81M | $105.47M | $100.68M | $89.17M | $75.16M | $46.27M | $59.25M | $59.84M | $56.26M | $99.62M | $46.97M | $37.12M | $35.44M | $31.27M |
| Neuro | $171.41M | $108.81M | $98.55M | $90.32M | $84.80M | $81.09M | $84.65M | $83.57M | $80.04M | $75.92M | $58.84M | $78.08M | $85.42M | $83.25M | $163.02M | $81.47M | $74.69M | $74.20M | $71.43M |
Penumbra's latest quarterly revenue breakdown by segment (product or service), as of Sep 23: Neuro (63.26%), and Peripheral Vascular (36.74%).
Penumbra Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| UNITED STATES | $757.15M | $591.72M | $527.79M | $400.27M | $355.22M |
| Non-US | $301.37M | $255.42M | $219.80M | $160.14M | - |
| JAPAN | - | - | - | - | $42.52M |
| Other Non-US | - | - | - | - | $149.66M |
Penumbra's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (71.53%), and Non-US (28.47%).
Quarterly Revenue by Country
| Country | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $226.33M | $218.18M | $209.64M | $203.68M | $194.82M | $186.77M | $171.88M | $148.82M | $141.46M | $144.31M | $134.83M | $128.40M | $120.07M | $109.66M | $78.04M | $95.77M | $96.06M | $90.27M | $168.88M | $82.51M |
| Other Non-US | $74.71M | $81.22M | $69.01M | $76.13M | $74.73M | $69.52M | $64.86M | $66.89M | $59.59M | $55.28M | $55.86M | $49.13M | $41.42M | $27.07M | $41.55M | $39.65M | $38.02M | $72.00M | $36.41M | - |
| JAPAN | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $9.55M | $11.21M | $21.75M | $9.52M |
Penumbra's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (75.18%), and Other Non-US (24.82%).
Penumbra Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| DXCM | DexCom | $3.62B | $994.20M |
| MASI | Masimo | $2.05B | $492.80M |
| PODD | Insulet | $1.70B | $488.50M |
| ITGR | Integer | $1.60B | $746.27M |
| CNMD | CONMED | $1.24B | $316.70M |
| LIVN | LivaNova | $1.15B | $318.11M |
| PEN | Penumbra | $1.06B | $301.04M |
| TNDM | Tandem Diabetes Care | $747.72M | $331.03M |
| SWAV | ShockWave Medical | $730.23M | $218.81M |
| INSP | Inspire Medical Systems | $624.80M | $195.88M |
| NARI | Inari Medical | $493.63M | $153.39M |
| IRTC | iRhythm | $492.68M | $147.54M |
| INMD | InMode | $492.05M | $80.28M |
| TMDX | TransMedics Group | $241.62M | $-12.24M |
PEN Revenue FAQ
What is Penumbra’s yearly revenue?
Penumbra's yearly revenue for 2023 was $1.06B, representing an increase of 24.95% compared to 2022. The company's yearly revenue for 2022 was $847.13M, representing an increase of 13.32% compared to 2021. PEN's yearly revenue for 2021 was $747.59M, representing an increase of 33.40% compared to 2020.
What is Penumbra’s quarterly revenue?
Penumbra's quarterly revenue for Q3 2024 was $301.04M, a 0.55% increase from the previous quarter (Q2 2024), and a 11.11% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $299.4M, a 7.45% increase from the previous quarter (Q1 2024), and a 14.49% increase year-over-year (Q2 2023). PEN's quarterly revenue for Q1 2024 was $278.66M, a -2.12% decrease from the previous quarter (Q4 2023), and a 15.43% increase year-over-year (Q1 2023).
What is Penumbra’s revenue growth rate?
Penumbra's revenue growth rate for the last 3 years (2021-2023) was 41.59%, and for the last 5 years (2019-2023) was 93.37%.
What are Penumbra’s revenue streams?
Penumbra's revenue streams in c 22 are Neuro, and Peripheral Vascular. Neuro generated $347.74M in revenue, accounting 41.05% of the company's total revenue, up 2.67% year-over-year. Peripheral Vascular generated $499.39M in revenue, accounting 58.95% of the company's total revenue, up 22.14% year-over-year.
What is Penumbra’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Penumbra was Peripheral Vascular. This segment made a revenue of $499.39M, representing 58.95% of the company's total revenue.